Jeito Capital (Jeito), an independent private equity firm dedicated to biotech and biopharma, has co-led a USD65 million Series A financing round in EyeBiotech Limited (EyeBio), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.
Jeito Capital (Jeito), an independent private equity firm dedicated to biotech and biopharma, has co-led a USD65 million Series A financing round in EyeBiotech Limited (EyeBio), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.
Jeito co-led the financing with SV Health Investors and Samsara BioCapital, with additional financial backing from MRL Ventures. Jeito Capital’s newly appointed Partner, Andreas Wallnoefer, will join EyeBio’s Board of Directors, Kate Bingham, Managing Partner at SV Health Investors, and Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital.
EyeBio was founded in August 2021 by David Guyer, MD, and Anthony P Adamis, MD, working with collaborators at SV Health Investors, who provided seed funding and helped to recruit leadership and to initiate pipeline development. Previously, Dr Guyer and Dr Adamis co-founded Eyetech Pharmaceuticals, where they developed and commercialized the first anti-vascular endothelial growth factor (anti-VEGF) drug for the treatment of age-related macular degeneration (AMD) in 2005.
